SEC Comment Letter for ALNYLAM PHARMACEUTICALS, INC. (ALNY) (CIK 0001178670) (ALNY) — Mar 21, 2019
ALNYLAM PHARMACEUTICALS, INC. (ALNY) (CIK 0001178670)
Date: March 21, 2019 · CIK: 0001178670 · Accession: 0000000000-19-005375
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-36407
Letter
March 20, 2019 John M. Maraganore, Ph.D. Chief Executive Officer Alnylam Pharmaceuticals, Inc. 300 Third Street Cambridge, MA 02142 Re:Alnylam Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 11, 2019 File No. 001-36407 Dear Dr. Maraganore: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Gregg L. Katz, Esq.
Show Raw Text
March 20, 2019
John M. Maraganore, Ph.D.
Chief Executive Officer
Alnylam Pharmaceuticals, Inc.
300 Third Street
Cambridge, MA 02142
Re:Alnylam Pharmaceuticals, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed March 11, 2019
File No. 001-36407
Dear Dr. Maraganore:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Gregg L. Katz, Esq.